Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amedisys inc. - AMED

AMED

Close Chg Chg %
92.84 0.14 0.15%

Closed Market

92.98

+0.14 (0.15%)

Volume: 131.15K

Last Updated:

Apr 2, 2025, 4:00 PM EDT

Trade Now

Company Overview: amedisys inc. - AMED

AMED Key Data

Open

$92.51

 Day Range

92.27 - 93.25

52 Week Range

82.17 - 98.95

 Market Cap

$3.05B

Shares Outstanding

32.81M

 Public Float

31.96M

Beta

0.89

 Rev. Per Employee

N/A

P/E Ratio

70.98

 EPS

$1.32

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

304.51K

  

AMED Performance

1 Week
 
 0.30%
 
1 Month
 
 1.07%
 
3 Months
 
 1.86%
 
1 Year
 
 0.30%
 
5 Years
 
 -47.37%
 

AMED Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About amedisys inc. - AMED

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

AMED At a Glance

Amedisys, Inc.
3854 American Way
Baton Rouge, Louisiana 70816
Phone 1-225-292-2031 Revenue 2.35B
Industry Medical/Nursing Services Net Income 43.23M
Sector Health Services 2024 Sales Growth 5.005%
Fiscal Year-end 12 / 2025 Employees 19,000
View SEC Filings

AMED Valuation

P/E Current 70.979
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 69.411
Price to Sales Ratio 1.278
Price to Book Ratio 2.623
Price to Cash Flow Ratio 13.537
Enterprise Value to EBITDA 13.584
Enterprise Value to Sales 1.363
Total Debt to Enterprise Value 0.144

AMED Efficiency

Revenue/Employee 123,596.00
Income Per Employee 2,275.316
Receivables Turnover 7.667
Total Asset Turnover 1.119

AMED Liquidity

Current Ratio 1.229
Quick Ratio 1.229
Cash Ratio 0.593

AMED Profitability

Gross Margin 20.011
Operating Margin 8.924
Pretax Margin 3.671
Net Margin 1.841
Return on Assets 2.059
Return on Equity 3.928
Return on Total Capital 2.712
Return on Invested Capital 2.862

AMED Capital Structure

Total Debt to Total Equity 40.483
Total Debt to Total Capital 28.817
Total Debt to Total Assets 21.476
Long-Term Debt to Equity 34.853
Long-Term Debt to Total Capital 24.809
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amedisys Inc. - AMED

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.21B 2.22B 2.24B 2.35B
Sales Growth
+6.88% +0.41% +0.59% +5.01%
Cost of Goods Sold (COGS) incl D&A
1.26B 1.29B 1.78B 1.88B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
30.90M 24.93M 23.85M 26.04M
Depreciation
12.10M 11.50M 18.20M 21.30M
Amortization of Intangibles
18.80M 13.44M 5.65M 4.74M
COGS Growth
+4.13% +1.67% +38.43% +5.57%
Gross Income
949.86M 937.84M 457.08M 469.93M
Gross Income Growth
+10.79% -1.27% -51.26% +2.81%
Gross Profit Margin
+42.90% +42.18% +20.44% +20.01%
2021 2022 2023 2024 5-year trend
SG&A Expense
703.58M 754.06M 26.08M 29.03M
Research & Development
- - - -
-
Other SG&A
703.58M 754.06M 26.08M 29.03M
SGA Growth
+6.89% +7.17% -96.54% +11.30%
Other Operating Expense
- - 237.93M 231.34M
-
Unusual Expense
7.66M 3.01M 142.67M 115.03M
EBIT after Unusual Expense
238.62M 180.77M 50.39M 94.54M
Non Operating Income/Expense
51.14M 1.70M 20.50M 22.44M
Non-Operating Interest Income
49.00K 178.00K 3.27M 8.11M
Equity in Earnings of Affiliates
4.95M (45.00K) 10.76M 6.27M
Interest Expense
9.53M 22.23M 31.27M 30.76M
Interest Expense Growth
-13.71% +133.36% +40.70% -1.63%
Gross Interest Expense
9.53M 22.23M 31.27M 30.76M
Interest Capitalized
- - - -
-
Pretax Income
280.23M 160.24M 39.62M 86.22M
Pretax Income Growth
+32.92% -42.82% -75.27% +117.59%
Pretax Margin
+12.66% +7.21% +1.77% +3.67%
Income Tax
70.06M 42.55M 50.56M 48.05M
Income Tax - Current - Domestic
25.48M 19.17M 29.90M 40.70M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
44.58M 23.38M 20.66M 7.35M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
4.95M (45.00K) 10.76M 6.27M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
210.17M 117.70M (10.94M) 38.16M
Minority Interest Expense
1.09M (910.00K) (1.19M) (5.07M)
Net Income
209.07M 118.61M (9.75M) 43.23M
Net Income Growth
+13.87% -43.27% -108.22% +543.53%
Net Margin Growth
+9.44% +5.34% -0.44% +1.84%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
209.07M 118.61M (9.75M) 43.23M
Preferred Dividends
- - - -
-
Net Income Available to Common
209.07M 118.61M (9.75M) 43.23M
EPS (Basic)
6.405 3.6476 -0.299 1.3213
EPS (Basic) Growth
+13.58% -43.05% -108.20% +541.91%
Basic Shares Outstanding
32.64M 32.52M 32.60M 32.72M
EPS (Diluted)
6.3409 3.6324 -0.299 1.308
EPS (Diluted) Growth
+14.89% -42.71% -108.23% +537.46%
Diluted Shares Outstanding
32.97M 32.65M 32.60M 33.05M
EBITDA
277.18M 208.72M 216.91M 235.61M
EBITDA Growth
+21.59% -24.70% +3.93% +8.62%
EBITDA Margin
+12.52% +9.39% +9.70% +10.03%

Snapshot

Average Recommendation HOLD Average Target Price 100.833
Number of Ratings 12 Current Quarters Estimate 1.37
FY Report Date 06 / 2025 Current Year's Estimate 4.764
Last Quarter’s Earnings 1.13 Median PE on CY Estimate N/A
Year Ago Earnings 4.32 Next Fiscal Year Estimate 5.187
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 13 11
Mean Estimate 1.37 1.15 4.76 5.19
High Estimates 1.57 1.35 5.27 5.68
Low Estimate 1.11 0.99 4.37 4.64
Coefficient of Variance 9.86 9.47 6.68 6.44

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 10 10 9
UNDERWEIGHT 0 0 0
SELL 1 1 0
MEAN Hold Hold Hold

Insider Actions for Amedisys Inc. - AMED

Date Name Shares Transaction Value
Mar 7, 2025 Allyson Guidroz Chief Accounting Officer 8,761 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $92.03 per share 806,274.83
Feb 20, 2025 Nick Muscato Chief Strategy Officer 36,661 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Allyson Guidroz Chief Accounting Officer 10,802 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.6 per share 1,000,265.20
Feb 20, 2025 Jennifer Guckert Griffin Chief Legal Officer 19,832 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Denise M. Bohnert Chief Compliance Officer 21,010 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.6 per share 1,945,526.00
Feb 20, 2025 Denise M. Bohnert Chief Compliance Officer 21,675 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Richard M. Ashworth President and CEO; Director 159,925 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Nick Muscato Chief Strategy Officer 36,010 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.6 per share 3,334,526.00
Feb 20, 2025 Scott G. Ginn EVP, CFO & COO 96,486 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $92.6 per share 8,934,603.60
Feb 20, 2025 Scott G. Ginn EVP, CFO & COO 98,281 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Jeffrey A. Rideout Director 7,645 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Bruce Devereau Perkins Director 22,407 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Julie D. Klapstein Director 14,341 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Ivanetta Davis Samuels Director 5,910 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Paul B. K. Kusserow Director 353,670 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Teresa L. Kline Director 8,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Vickie L. Capps Director 8,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Molly Joel Coye Director 7,128 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Amedisys Inc. in the News